Jump to content

Drilldown: Medicines

Pharmacopedia
BrowseCategoriesLog in

Choose a table:


Medicines > classes : Benzodiazepine or [[:Category:SGLT2_inhibitors|SGLT2 inhibitor]] & routes: Oral

Use the filters below to narrow your results.

generic:
Alprazolam (1) · Dapagliflozin (1) · Empagliflozin (1)
brand:
Farxiga (US), Forxiga (international) (1) · Jardiance (1) · Xanax (1)
classes: (Click arrow to add another value)
mechanism:
None (2) · GABA-A positive allosteric modulator'"`UNIQ--ref-00000067-QINU`"' '"`UNIQ--vote-00000068-QINU`"' (1)
uses:
'"`UNIQ--vote-00000069-QINU`"', '"`UNIQ--vote-0000006A-QINU`"', '"`UNIQ--vote-0000006B-QINU`"' (1) · '"`UNIQ--vote-00000278-QINU`"', '"`UNIQ--vote-00000279-QINU`"', '"`UNIQ--vote-0000027A-QINU`"', '"`UNIQ--vote-0000027B-QINU`"' (1) · '"`UNIQ--vote-0000054E-QINU`"', '"`UNIQ--vote-0000054F-QINU`"', '"`UNIQ--vote-00000550-QINU`"', '"`UNIQ--vote-00000551-QINU`"' (1)
starting dose:
0.25 mg (1) · 10 mg PO once daily in the morning; 5 mg starting in heart failure (1) · 10 mg PO once daily in the morning; may titrate to 25 mg for additional glycemic effect (1)
preparations:
0.25 mg, 0.5 mg, 1 mg, 2 mg tablets (immediate-release and orally disintegrating); 0.5 mg, 1 mg, 2 mg, 3 mg extended-release tablets; 1 mg/mL oral concentrate (1) · 10 mg, 25 mg tablets (1) · 5 mg, 10 mg tablets (1)
fda max:
10 mg/d (2) · 25 mg/d (1)
routes: (Click arrow to add another value)
onset:
30-60 min (immediate-release); 1-2 h (extended-release) (1) · Glycosuria within hours; HbA1c effect at 12 weeks; cardiovascular and renal benefits over months (1) · Glycosuria within hours; HbA1c effect at 12 weeks; CV/renal benefits over months (1)
duration:
24 hours (2) · 6 h (immediate-release); ~11 h (extended-release) (1)
halflife:
11-13 h (immediate-release); 11-16 h (extended-release) (1) · ~12.4 hours'"`UNIQ--ref-0000027C-QINU`"' (1) · ~12.9 hours'"`UNIQ--ref-00000552-QINU`"' (1)
bioavailability:
80-90% oral (1) · High (oral; not affected by food, but typically given with the morning meal)'"`UNIQ--ref-0000027D-QINU`"' (1) · ~78% (oral; high-fat meal modestly reduces but is not clinically significant)'"`UNIQ--ref-00000553-QINU`"' (1)
pregnancy:
Avoid in second and third trimesters; fetal SGLT2 inhibition disrupts kidney development.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (2) · Category D'"`UNIQ--ref-0000006C-QINU`"' (1)
legal:
Schedule IV (US) (1) · [[USLegal:Prescription only|Rx-only]] in US (2)

Showing below up to 3 results in range #1 to #3.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"